[go: up one dir, main page]

NO20054219L - Inaktivert Nodavirus-vaksine - Google Patents

Inaktivert Nodavirus-vaksine

Info

Publication number
NO20054219L
NO20054219L NO20054219A NO20054219A NO20054219L NO 20054219 L NO20054219 L NO 20054219L NO 20054219 A NO20054219 A NO 20054219A NO 20054219 A NO20054219 A NO 20054219A NO 20054219 L NO20054219 L NO 20054219L
Authority
NO
Norway
Prior art keywords
vaccine
inactivated
inactivated nodavirus
nodavirus vaccine
fish
Prior art date
Application number
NO20054219A
Other languages
English (en)
Other versions
NO20054219D0 (no
NO336878B1 (no
Inventor
Nuno Dos Santos
Jacqueline Ireland
Andrew Cartner Barnes
Michael Horne
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32910468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20054219(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0303867A external-priority patent/GB0303867D0/en
Priority claimed from GB0320195A external-priority patent/GB0320195D0/en
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Publication of NO20054219L publication Critical patent/NO20054219L/no
Publication of NO20054219D0 publication Critical patent/NO20054219D0/no
Publication of NO336878B1 publication Critical patent/NO336878B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/30011—Nodaviridae
    • C12N2770/30061—Methods of inactivation or attenuation
    • C12N2770/30063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En vaksine mot nodavimsinfeksjon i fisk kan produseres ved å inaktivere vimset ved å anvende en aziridinforbindelse. Denne vaksine kan anvendes for å forebygge viral nervøs nekrose (VNN) i en rekke fiskearter.
NO20054219A 2003-02-19 2005-09-12 Inaktivert piscine viralt nervenekrosevirus stamme, vaksine og anvendelse derav. NO336878B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0303867A GB0303867D0 (en) 2003-02-19 2003-02-19 Organic compounds
GB0320195A GB0320195D0 (en) 2003-08-28 2003-08-28 Organic compounds
PCT/EP2004/001543 WO2004074467A1 (en) 2003-02-19 2004-02-18 Inactivated nodavirus vaccine

Publications (3)

Publication Number Publication Date
NO20054219L true NO20054219L (no) 2005-09-12
NO20054219D0 NO20054219D0 (no) 2005-09-12
NO336878B1 NO336878B1 (no) 2015-11-23

Family

ID=32910468

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054219A NO336878B1 (no) 2003-02-19 2005-09-12 Inaktivert piscine viralt nervenekrosevirus stamme, vaksine og anvendelse derav.

Country Status (17)

Country Link
US (2) US20060257425A1 (no)
EP (1) EP1597359B1 (no)
JP (1) JP4664901B2 (no)
AT (1) ATE437224T1 (no)
AU (1) AU2004213566B2 (no)
CA (1) CA2512930C (no)
CL (1) CL2004000282A1 (no)
CY (1) CY1109344T1 (no)
DE (1) DE602004022139D1 (no)
DK (1) DK1597359T3 (no)
ES (1) ES2328141T3 (no)
MY (1) MY143785A (no)
NO (1) NO336878B1 (no)
PT (1) PT1597359E (no)
SI (1) SI1597359T1 (no)
TW (1) TWI347364B (no)
WO (1) WO2004074467A1 (no)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2008003262A1 (es) * 2007-11-02 2009-06-26 Intervet Int Bv Vacuna que comprende lactococcus garviae, pasteurella piscicida, vibrio anguillarum y nocardia seriolae; y uso de dichas bacterias para combatir infecciones de nocardia en peces.
KR101608121B1 (ko) * 2012-09-20 2016-04-01 중앙대학교 산학협력단 노다바이러스의 바이러스 유사입자의 생산방법, 이를 발현하는 효모 세포주 및 이를 포함하는 백신 조성물
KR101414009B1 (ko) * 2012-11-16 2014-07-02 주식회사 젠닥스 형질전환 식물체를 이용한 어류 바이러스성 신경괴사증 예방 경구백신 제조방법과 그에 따른 식물체
US9884103B2 (en) * 2013-05-28 2018-02-06 Elanco Tiergesundheit Ag Interactions of betanodaviruses in infection
ES2795040T3 (es) * 2016-02-02 2020-11-20 Benchmark Animal Health Ltd Métodos para producir virus
CN113429338B (zh) * 2021-05-20 2023-05-02 陕西泰合利华工业有限公司 一种合成氟吡菌酰胺的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
WO1999050419A2 (en) * 1998-03-31 1999-10-07 University Of Maryland Biotechnology Institute A method for generating nonpathogenic, infectious pancreatic necrosis virus (ipnv) from synthetic rna transcripts
TWI220904B (en) * 1998-12-03 2004-09-11 Nat Science Council An immortal cell line derived from grouper Epinephelus coioides and its applications therein
US20040001863A1 (en) * 1998-12-03 2004-01-01 Shau-Chi Chi Immortal cell line derived from grouper Epinephelus coioides and its applications therein
JP2001161355A (ja) * 1999-11-25 2001-06-19 Natl Sci Council ハタ科チャイロマルハタから得られる不死の細胞株およびその応用
AU2002233969A1 (en) * 2001-12-07 2003-06-23 Schweitzer Chemical Corporation Usa Vaccines and antibodies produced from viruses derived from an immortal cell line of grouper epinephelus coioides
US20050118194A1 (en) * 2003-12-01 2005-06-02 Sin Yoke M. Oral vaccine, method for its preparation and use thereof

Also Published As

Publication number Publication date
US8124100B2 (en) 2012-02-28
US20060257425A1 (en) 2006-11-16
AU2004213566A1 (en) 2004-09-02
CA2512930C (en) 2015-06-02
TWI347364B (en) 2011-08-21
AU2004213566B2 (en) 2007-08-23
ES2328141T3 (es) 2009-11-10
CL2004000282A1 (es) 2005-03-28
DK1597359T3 (da) 2009-11-16
EP1597359A1 (en) 2005-11-23
HK1085765A1 (en) 2006-09-01
JP2006517943A (ja) 2006-08-03
EP1597359B1 (en) 2009-07-22
WO2004074467A1 (en) 2004-09-02
ATE437224T1 (de) 2009-08-15
PT1597359E (pt) 2009-08-06
JP4664901B2 (ja) 2011-04-06
MY143785A (en) 2011-07-15
CA2512930A1 (en) 2004-09-02
DE602004022139D1 (no) 2009-09-03
SI1597359T1 (sl) 2009-12-31
NO20054219D0 (no) 2005-09-12
US20090288179A1 (en) 2009-11-19
CY1109344T1 (el) 2014-07-02
TW200425899A (en) 2004-12-01
NO336878B1 (no) 2015-11-23

Similar Documents

Publication Publication Date Title
CY1109344T1 (el) Εμβολιο αδρανοποιημενου nodavirus
EA200900156A1 (ru) Пиридазиновое соединение (варианты), способ его получения (варианты), способ лечения или профилактики инфекционного вирусного гепатита с с его помощью, композиция и лекарственное средство на его основе
WO2004060308A3 (en) Thiosemicarbazones as anti-virals and immunopotentiators
BRPI0514176A (pt) inibidores de replicação de hcv
DK1654261T3 (da) Hepatitis C-inhibitorforbindelser
EA200700243A1 (ru) Способы лечения гепатита с
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
DK1569929T3 (da) Forbindelser og fremgangsmåder til behandling eller forebyggelse af flavi-virusinfektioner
CY1113038T1 (el) Τριετεροκυκλικες ενωσεις, συνθεσεις, και μεθοδοι για τη θεραπεια καρκινου
TW200730478A (en) N-(6-membered aromatic ring)-amido anti-viral compounds
EA201000277A1 (ru) Соединения для лечения гепатита с
EA200800932A1 (ru) Модифицированные 4`-нуклеозиды в качестве противовирусных агентов
GEP20063938B (en) Hepatitis c virus inhibitors
ECSP045300A (es) Antígenos virales
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
ATE365206T1 (de) Verfahren zur entwicklung von einem hiv impfstoff
CO2022006965A2 (es) Inhibidores de egfr
ATE455124T1 (de) Rekombinante vesicular stomatitis viren als impstoff gegen virale hämorrhagische fieber
WO2019222238A3 (en) Substituted 2,2'-bipyrimidinyl compounds, analogues thereof, and methods using same
EA200801251A1 (ru) Вакцины против гриппа, адсорбированные на алюминиевых адъювантах, для немедленного приёма
WO2007067517A3 (en) Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants
ATE401392T1 (de) Subtypabgestimmte inaktivierte vollvirusvakzine zur behandlung von patienten mit hiv-infektion
AR019785A1 (es) Pestivirus no diseminantes
ATE359815T1 (de) Streptococcus-phocae-vakzine

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: NOVARTIS TIERGESUNDHEIT AG, CH

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: ELANCO TIERGESUNDHEIT AG, CH